The antiviral lectin Griffithsin (GRFT) has broad-spectrum activity against human immunodeficiency viruses (HIV) types 1 and 2, herpes simplex virus type 2 (HSV-2) and hepatitis C virus (HCV). The product target is a rectal microbicide gel, containing GRFT as the primary Active Pharmaceutical Ingredient (API).
Preclinical – Early (Pre1)
Delivery Route & Method:
Topical - Gel-Rectal
Mechanism of Action:
Recombinant non-ARV live biotherapeutic product, manufactured in tobacco plants.
- University of Louisville
- Nat. Institute Allergy & Infect. Diseases (NIAID)
- Griffithsin (GRFT)